06 May 2026
06 May 2026
As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra.
Pharmaceutical Technology rounds up the key readouts from the 2026 Digestive Disease Week conference held in Chicago.
The FDA granted breakthrough therapy designation to TERN-701 for adults with Philadelphia chromosome-positive CML without the T315I mutation.
Non-viral gene therapies may ease some safety, pricing and manufacturing challenges linked to viral vectors, but experts say both approaches will still have a place.
This acquisition marks UCB’s second foray into the TCE space – closely following a blockbuster licensing deal with TCE specialist, Antengene.
Langlara is manufactured by Sunshine Lake Pharma, part of the HEC Group and commercialised in the US via Lanexa Biologics.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
